Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609358 | 0.86 | HTT (0.65) | ALDH1A1LMNAHPGDRAPGEF4MEN1 | |
| SCHEMBL18415468 | 0.81 | ALDH1A1 (0.87) | ALDH1A1LMNAHPGDPKMRAPGEF4 | |
| SCHEMBL4448022 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDRAPGEF4NLRP3 | |
| SCHEMBL2094230 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDPKMRAPGEF4 | |
| SCHEMBL28276803 | 0.80 | LMNA (0.46) | ALDH1A1LMNAHPGDNLRP3MEN1 | |
| SCHEMBL27478662 | 0.79 | LMNA (0.68) | ALDH1A1LMNAHPGDMEN1POLB | |
| SCHEMBL28276819 | 0.79 | LMNA (0.41) | ALDH1A1LMNAHPGDPKMRAPGEF4 | |
| SCHEMBL2902943 | 0.79 | ALDH1A1 (0.63) | ALDH1A1LMNAHPGDRAPGEF4LCK | |
| SCHEMBL2094227 | 0.79 | ALDH1A1 (0.63) | ALDH1A1LMNAHPGDPKMRAPGEF4 | |
| SCHEMBL18183214 | 0.78 | LMNA (0.39) | ALDH1A1LMNAHPGDPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848658-B1 | INK COMPOSITION, INKJET RECORDING INK, AND INKJET RECORDING METHOD | FUJIFILM CORP (JP) | 2017-04-05 | — | — | EP | disclosed |
| CN-104334655-B | Ink composition, ink for inkjet recording, and inkjet recording method | 富士胶片株式会社 | 2016-11-16 | — | — | CN | disclosed |
| US-9206326-B2 | Ink composition, inkjet recording ink, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2848658-A1 | INK COMPOSITION, INK FOR INKJET RECORDING, AND INKJET RECORDING METHOD | FUJIFILM Corporation (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20150062265-A1 | INK COMPOSITION, INKJET RECORDING INK, AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| CN-104334655-A | Ink composition, ink for inkjet recording, and inkjet recording method | FUJIFILM CORP | 2015-02-04 | — | — | CN | disclosed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-1320365-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | Bristol-Myers Squibb Company (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6515005-B2 | For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-31 | — | — | US | disclosed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002024200-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | ALDH1A1 2429/4885LMNA 2856/4885HPGD 3242/4885 |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | CRH, CRHR1, CRHR2 | ALDH1A1 1902/4885LMNA 4482/4885HPGD 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.